Bristol-Myers Squibb Co (BMY)
55.19
+0.87
(+1.60%)
USD |
NYSE |
Nov 04, 13:06
Bristol-Myers Squibb Revenue (Quarterly): 11.89B for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 11.89B |
| June 30, 2024 | 12.20B |
| March 31, 2024 | 11.86B |
| December 31, 2023 | 11.48B |
| September 30, 2023 | 10.97B |
| June 30, 2023 | 11.23B |
| March 31, 2023 | 11.34B |
| December 31, 2022 | 11.41B |
| September 30, 2022 | 11.22B |
| June 30, 2022 | 11.89B |
| March 31, 2022 | 11.65B |
| December 31, 2021 | 11.98B |
| September 30, 2021 | 11.62B |
| June 30, 2021 | 11.70B |
| March 31, 2021 | 11.07B |
| December 31, 2020 | 11.07B |
| September 30, 2020 | 10.54B |
| June 30, 2020 | 10.13B |
| March 31, 2020 | 10.78B |
| December 31, 2019 | 7.945B |
| September 30, 2019 | 6.007B |
| June 30, 2019 | 6.273B |
| March 31, 2019 | 5.92B |
| December 31, 2018 | 5.973B |
| September 30, 2018 | 5.691B |
| Date | Value |
|---|---|
| June 30, 2018 | 5.704B |
| March 31, 2018 | 5.193B |
| December 31, 2017 | 5.449B |
| September 30, 2017 | 5.254B |
| June 30, 2017 | 5.144B |
| March 31, 2017 | 4.929B |
| December 31, 2016 | 5.243B |
| September 30, 2016 | 4.922B |
| June 30, 2016 | 4.871B |
| March 31, 2016 | 4.391B |
| December 31, 2015 | 4.287B |
| September 30, 2015 | 4.069B |
| June 30, 2015 | 4.163B |
| March 31, 2015 | 4.041B |
| December 31, 2014 | 4.258B |
| September 30, 2014 | 3.921B |
| June 30, 2014 | 3.889B |
| March 31, 2014 | 3.811B |
| December 31, 2013 | 4.441B |
| September 30, 2013 | 4.065B |
| June 30, 2013 | 4.048B |
| March 31, 2013 | 3.831B |
| December 31, 2012 | 4.191B |
| September 30, 2012 | 3.736B |
| June 30, 2012 | 4.443B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
7.945B
Minimum
Dec 2019
12.20B
Maximum
Jun 2024
11.20B
Average
11.37B
Median
Revenue (Quarterly) Benchmarks
| Amgen Inc | 8.503B |
| Johnson & Johnson | 22.47B |
| Eli Lilly and Co | 11.44B |
| Merck & Co Inc | 16.66B |
| Pfizer Inc | 17.70B |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 1.211B |
| Total Expenses (Quarterly) | 9.72B |
| EPS Diluted (Quarterly) | 0.60 |
| Enterprise Value | 151.89B |
| Gross Profit Margin (Quarterly) | 75.13% |
| Profit Margin (Quarterly) | 10.18% |
| Earnings Yield | -6.50% |
| Operating Earnings Yield | 6.50% |
| Normalized Earnings Yield | 2.892 |